FOCUS Data Coordinating Center
FOCUS Data Coordinating Center
批准号:
7476177
负责人:
MICHAEL L TERRIN
金额:
$6.3万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-10 至 2011-10-31
关键词:
Adverse effectsAnemiaAntibiotic ProphylaxisBloodBlood CellsBlood TransfusionCardiovascular systemCaringCessation of lifeConfidence IntervalsDataData Coordinating CenterDay SurgeryDiseaseEnrollmentErythrocyte TransfusionErythrocytesFailureFractureFrail ElderlyFrequenciesGoalsHIVHematocrit procedureHemoglobinHemoglobin concentration resultHepatitisHip FracturesHospitalsHumanLower ExtremityMeasuresMedicalMedical ErrorsMorbidity - disease rateMyocardial InfarctionNumbersNursing HomesOperative Surgical ProceduresOutcomePatientsPlacementPneumoniaPopulationPostoperative ComplicationsPostoperative PeriodProphylactic treatmentRandomizedRandomized Clinical TrialsRandomized Controlled Clinical TrialsRecovery of FunctionRelative (related person)Research PersonnelRiskRisk ReductionSafetySamplingSiteStandards of Weights and MeasuresStrokeSymptomsTestingThromboembolismTransfusionUnited StatesWalkingWhole Bloodbasedayfallsfootfunctional outcomesimprovedinstrumental activity of daily livingmortalityprogramsrepaired
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Over 11 million red blood cell units are transfused in the United States annually. Despite the common use of red
blood cell transfusions, the threshold for transfusion has not been adequately evaluated. A decade ago the standard
of care was to administer a peri-operative transfusion whenever the hemoglobin level fell below 10 g/dl (the "10/30
rule"). Concerns about the safety of blood, especially with respect to HIV and hepatitis, and the absence of data to
support a 10 g/dl threshold led to the current standard of care to administer blood transfusions based on the
presence of symptoms and not a specific hemoglobin/hematocrit level. However, there are no randomized clinical
trials in surgical patients that have tested the efficacy and safety of withholding blood until the patient develops
symptoms or of the "10/30" approachto transfusion and limited evidence for patients with underlyingcardiovascular
disease who are at greatest risk of adverse effects from reduced hemoglobin levels.
We propose to conduct a multi-center randomized trial to test if a more aggressive transfusion strategy that
maintains postoperative hemoglobin levels above 10 g/dl improves patient outcome as compared to a more
conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia. Patients
eligible for the trial will have undergone surgical repair for a hip fracture and have a postoperative hemoglobin level
below 10 g/dl within three days of surgery. Only patients with cardiovascular diseasewill be entered into the study.
Symptomatic transfusion strategy patients will receivered blood cell transfusions for symptoms of anemia, although
transfusion is also permitted, but not required, if the hemoglobin level falls below 8 g/dl. Outcomes will include
functional recovery {primary outcome: ability to walk ten feet across a room without human assistance at 60-days
post-randomization), long-term survival, nursing home placement, and postoperative complications (death in hospital
or within 30 days, pneumonia, myocardial infarction, thromboembplism, stroke). We will-enroll 2,600 patients over
a 3.5-year period to detect a reduction in the loss of ability to walk independently from 43% to 36% (16% relative
risk reduction) with power about 0.90.
Also, this study will measure the frequency and 95% confidence intervals of medical errors that are important in this
patient population. The medical errorsthat will be measuredare: transfusion errors (blood transfusion to the wrong
patient, mislabeling of samples for type and cross match, use of whole blood instead of packed red cells), failure to
use thromboembolism prophylaxis, incorrect antibiotic prophylaxis, wrong site surgery, and femoral shaft fracture.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Consortium-Wide Coordinating Core
-
批准号:10401457
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2020
-
负责人:MICHAEL L TERRIN
-
依托单位:
Consortium-Wide Coordinating Core
-
批准号:10845824
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2020
-
负责人:MICHAEL L TERRIN
-
依托单位:
Consortium-Wide Coordinating Core
-
批准号:10194365
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2020
-
负责人:MICHAEL L TERRIN
-
依托单位:
PCTC Administrative Coordinating Center
-
批准号:10010429
-
项目类别:
-
资助金额:$118.42万
-
财政年份:2016
-
负责人:MICHAEL L TERRIN
-
依托单位:
PCTC Administrative Coordinating Center
-
批准号:9355221
-
项目类别:
-
资助金额:$52.68万
-
财政年份:2016
-
负责人:MICHAEL L TERRIN
-
依托单位:
PCTC Administrative Coordinating Center
-
批准号:9486998
-
项目类别:
-
资助金额:$114.54万
-
财政年份:2016
-
负责人:MICHAEL L TERRIN
-
依托单位:
PCTC Administrative Coordinating Center
-
批准号:9221092
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2016
-
负责人:MICHAEL L TERRIN
-
依托单位:
Azithromycin To Prevent BPD In Ureaplasma-Infected Preterms
-
批准号:9262594
-
项目类别:
-
资助金额:$67.9万
-
财政年份:2011
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:7834466
-
项目类别:
-
资助金额:$237.07万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:8105340
-
项目类别:
-
资助金额:$222.9万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:8842683
-
项目类别:
-
资助金额:$351.74万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:7939718
-
项目类别:
-
资助金额:$406.27万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:8265266
-
项目类别:
-
资助金额:$583.54万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Progenitor Cell Biology Consortium Administrative Coordinating Center
-
批准号:8656741
-
项目类别:
-
资助金额:$520.23万
-
财政年份:2009
-
负责人:MICHAEL L TERRIN
-
依托单位:
Doxycycline Treatment of Abdominal Aortic Aneurysm: Planning
-
批准号:7255910
-
项目类别:
-
资助金额:$10.1万
-
财政年份:2007
-
负责人:MICHAEL L TERRIN
-
依托单位:
FOCUS Data Coordinating Center
-
批准号:6993262
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2003
-
负责人:MICHAEL L TERRIN
-
依托单位:
FOCUS Data Coordinating Center
-
批准号:7260323
-
项目类别:
-
资助金额:$92.9万
-
财政年份:2003
-
负责人:MICHAEL L TERRIN
-
依托单位:
FOCUS Data Coordinating Center
-
批准号:7093138
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2003
-
负责人:MICHAEL L TERRIN
-
依托单位:
FOCUS Data Coordinating Center
-
批准号:7688332
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2003
-
负责人:MICHAEL L TERRIN
-
依托单位:
FOCUS Data Coordinating Center
-
批准号:6323923
-
项目类别:
-
资助金额:$39.68万
-
财政年份:2003
-
负责人:MICHAEL L TERRIN
-
依托单位:
国内基金
海外基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
-
批准号:82302715
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:熊泽康
-
依托单位:
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:陈英伟
-
依托单位:
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
-
批准号:31200592
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:孙伟力
-
依托单位: